Humana (HUM) Stock Forecast & Price Target

Humana is positioned favorably because its deep specialization in government-sponsored coverage, especially Medicare Advantage, gives it a durable competitive niche while its broader healthcare services platform in primary care, at-home services, and pharmacy benefit management supports a more integrated and value-based model. The fundamental thesis is strengthened by management’s reaffirmed confidence in a multi-year earnings recovery, with early indicators for new and returning members—utilization, risk scores, inpatient admissions, and Rx trends—tracking in line to better than guidance, April trends appearing stable as of 4/29/26, and 1Q26 results coming in generally in line to slightly above consensus with a better-than-expected MLR and stronger investment income. The company also has meaningful margin-recovery optionality, including an estimated 560 BPS of Individual MA margin expansion available across CY27-CY28, support from plan finder and CY27 Star Ratings catalysts in 2H26, and balance-sheet actions that reduced more than $3 billion of subsidiary capital contribution requirements for 2026 and added $1 billion of junior subordinated notes to help fund 2027 maturities.

Humana is facing a fundamentally weaker earnings setup because its insurance segment is expected to see medical loss ratio deterioration through 2026, with management effectively guiding toward roughly 6.0% medical trend and seasonal pressure that could compound alongside Stars headwinds and higher utilization. Its CenterWell businesses do not offset that pressure enough, as CenterWell PCO was only breakeven to slightly negative in CY25, The Villages Health is expected to be a $70.0M operating income headwind in CY26, and MaxHealth only modestly benefits the year after incurring transaction and integration costs in 1Q26. In addition, the company is exposed to meaningful regulatory and reimbursement risk in Medicare Advantage, where intensified competition, possible benchmark or coding reductions, and uncertainty around risk adjustment and Stars bonus recovery create a difficult path to sustaining margins and earnings quality.